The subject matter of the present invention is a photopolymerizable liquid composition comprising at least one epoxidized polybutadiene prepolymer, at least one cationic photoinitiator, and at least one thioxanthone-derived photosensitizer, which can, for example, be in the form of a liquid dressing. The subject matter of the invention is also a process for obtaining a polymerized film from said photopolymerizable liquid composition, characterized in that said composition is applied to tissues such as the skin, the skin appendages or the mucous membranes so as to form a uniform liquid film, and the film thus obtained is subjected to ultraviolet radiation, preferably ultraviolet-visible radiation having a wavelength of between 380 and 405 nm, preferably between 385 and 395 nm.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

The invention provides a dry biocompatible film comprising at least one film forming material and particulate egg shell membrane (ESM), wherein said particulate ESM is distributed substantially uniformly in and/or on the film and wherein said film, or portion thereof, disintegrates upon contact with a wound or an exudate thereof. The invention further provides methods for preparing the films of the invention and the uses thereof in methods to promote the healing of wounds.

The present invention relates to a wound dressing material comprising a fibrillated acellular dermis matrix and a biodegradable polymer aqueous solution and, more specifically, to: a wound dressing material comprising 5-20 wt % of a fibrillated acellular dermis matrix, 0.5-5 wt % of a biodegradable polymer, and 75-94.5 wt % of water; and a preparation method therefor.

The present disclosure relates to a composition of an engineered biomaterial including extracellular matrix components of a mammalian tissue and a polymer; method of wound healing; and methods delivering therapeutic agents, growth factors, or hydration for wound healing to a subject in need thereof.

A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction.

The present invention relates to a packaged probiotic composition which is useful for treating or preventing bacterial colonisation in wounds and tissue. A characteristic feature of the invention is that the probiotic composition contains a probiotic microorganism which is in direct contact with water during storage of the probiotic composition. The invention furthermore pertains to methods of using and producing the probiotic composition.

One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.

A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.